PT 17
Latest Information Update: 23 Mar 2007
At a glance
- Originator Palatin Technologies
- Class Anti-inflammatories; Anti-ischaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation; Ischaemia
Most Recent Events
- 29 Jan 2002 Preclinical development for Inflammation in USA (Unknown route)
- 29 Jan 2002 Preclinical development for Ischaemia in USA (Unknown route)